DIA
OREX

Denver Investment Advisors’s Orexigen Therapeutics, Inc. OREX Stock Holding History

Denver Investment Advisors’s Portfolio OREX Stock Details OREX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-2,554
Closed -$44K – 554
2015
Q4 		$44K Sell
2,554
-290
-10% -$6.92K ﹤0.01% 498
2015
Q3 		$60K Sell
2,844
-97
-3% -$3.32K ﹤0.01% 524
2015
Q2 		$146K Buy
2,941
+1,124
+62% +$67.2K 0.01% 524
2015
Q1 		$142K Sell
1,817
-1,318
-42% -$81.8K ﹤0.01% 602
2014
Q4 		$190K Buy
3,135
+13
+0.4% +$653 0.01% 576
2014
Q3 		$133K Buy
3,122
+176
+6% +$9.45K ﹤0.01% 574
2014
Q2 		$182K Buy
+2,946
New +$171K 0.01% 560

Other funds holding OREX

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
FCMI
Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return
SC
Samlyn Capital New York $5.86B AUM 36.3% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Denver Investment Advisors's OREX Position: Q1 2016 in Review

Denver Investment Advisors sold out of Orexigen Therapeutics, Inc. (OREX) in Q1 2016, closing a stake of 2,554 shares — an estimated $44K sold.

Denver Investment Advisors first reported a position in OREX in Q2 2014 and held it in 7 quarters. The position peaked at $190K in Q4 2014. 104 funds tracked by Wall St. Rank hold OREX as of Q1 2016.

  • Denver Investment Advisors reported no remaining Orexigen Therapeutics, Inc. position as of Q1 2016 after selling out during the quarter.
  • Denver Investment Advisors sold 2,554 Orexigen Therapeutics, Inc. shares in Q1 2016, an estimated $44K.
  • Denver Investment Advisors first reported a position in Orexigen Therapeutics, Inc. in Q2 2014 and held it in 7 quarters.
  • Denver Investment Advisors's Orexigen Therapeutics, Inc. position peaked at $190K in Q4 2014.
  • 104 funds tracked by Wall St. Rank held Orexigen Therapeutics, Inc. as of Q1 2016.

Based on Denver Investment Advisors's 13F filing for Q1 2016, filed 12 May 2016.